print   Bookmark and Share  |  RSS  |  A  A  A

Cross Cutting Initiatives

Cross cutting initiatives bring together leading scientists and researchers at Winship and throughout Emory University with innovative technology and industry. This sharing of knowledge, resources, and expertise is the driver that accelerates progress and leads to life saving cancer therapies.
 
Georgia is  an environment rich with intellectual and institutional resources. The American Cancer Society, Yerkes Primate Center, The Center for Disease Control, Georgia Institute of Technology, just to name a few, are all located here and actively involved in cancer research. In addition to organizational collaborations, Winship's strong community network  strengthens a collaborative care model that maximizes access to cancer clinical trials, while supporting individual care close to home.
  1. Health Disparities Initiative
  2. Head and Neck Cancer SPORE
  3. Cancer Nanotechnology Platform Partnerships
  4. The Atlanta Clinical and Translational Science Institute (ACTSI)
  5. Cancer Genome Atlas Project
  6. Bio-Medical Engineering
  7. Georgia CORE State-wide Breast Cancer Trial Collaborative
  8. Georgia Tech & Emory Center for Regenerative Medicine
  9. Emory University and Georgia Tech Research Partnership

 


Health Disparities Initiative 

The Winship Cancer Institute of Emory University established a focus on cancer health disparities that would serve as a cross-cutting theme for the center to address the cancer health disparities documented across the state of Georgia, and as a means to facilitate inter-programmatic interactions.

The goals of the Winship Health Disparities Initiative (HDI) are:

  1. to initiate, enable, and sustain research and related activities that address issues relevant to cancer health disparities;
  2. to promote and facilitate Winship inter-programmatic interactions that encompass health disparities;
  3. to build collaborations among other academic, healthcare, community-based, federal and state agencies, and other partners that will contribute to research and other activities that may serve to address and reduce cancer health disparities in Georgia and the region.          

Learn More

Back to top


 Head and Neck Cancer SPORE

Visit the Head and Neck Cancer SPORE website

Specialized Programs of Research Excellence (SPOREs) are funded by the National Institutes of Health and the National Cancer Institute through specialized center grants (P50s) that promote interdisciplinary research and move basic research findings from the laboratory to clinical settings, involving both cancer patients and populations at risk of cancer. The purpose of Emory University's Head and Neck Cancer SPORE is to accelerate discovery in HNC research at Emory University, and to move these new discoveries into patients more rapidly than currently possible, with the overall objective of decreasing the morbidity, suffering, disability and death caused by this disease.
 
The Head and Neck Cancer SPORE uses an interdisciplinary approach to meet its objectives by carrying out projects with co-investigators in basic, translational, and clinical science. All projects test theories about biology, prevention, molecularly and nanotechnology-driven novel therapeutic approaches. Our four main research projects are: (1) Chemoprevention with Green Tea Polyphenon E and EGFR-TKIs in HNC; (2) Targeting Death Receptor-Mediated Apoptosis for HNC; (3) Development of Novel Curcumin Analogs for the Treatment of HNC; and (4) Biodegradable Nanoparticle-Formulated Taxol for Targeted Therapy of HNC. Each project in our SPORE program is centered on clearly defined translational objectives including pilot clinical trials.

SPORE in Head and Neck Cancer RFP -   Outline of Both Programs
 

Back to top


Cancer Nanotechnology Platform Partnerships (CNPPs)

The NCI Alliance for Nanotechnology in Cancer is part of the Center for Strategic Scientific Initiatives within the National Cancer Institute (NCI). The Alliance is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, treat and prevent cancer. Emory and Winship researchers have been awarded two Cancer Nanotechnology Platform Partnerships (CNPPs). These partnerships enable multi-disciplinary team research with the goal of addressing major barriers and answering  fundamental questions.

Theranostic Nanoparticles for Targeted Treatment of Pancreatic Cancer
Emory University
Principal Investigators: Lily Yang, M.D., Ph.D., and Hui Mao, Ph.D.

Toxicity and Efficacy of Gold Nanoparticle Photothermal Therapy in Cancer
Emory University
Principal Investigators: Dong Shin, M.D., and Mostafa El-Sayed, Ph.D.

Back to top


The Atlanta Clinical and Translational Science Institute (ACTSI)

The Atlanta Clinical and Translational Science Institute (ACTSI) is led by Emory University, in collaboration with Morehouse School of Medicine, Georgia Institute of Technology, and Children’s Healthcare of Atlanta. These institutions are already partners in healthcare, education, and cutting-edge, interdisciplinary research.
Funded through Clinical and Translational Science Awards (CTSAs), a national consortium that is transforming how clinical and translational research is conducted. Comprised of 38 academic health centers in 23 states, the consortium will link about 60 institutions together. This new program draws on the National Institute of Health’s (NIH’s) initiatives to re-engineer clinical research that will ultimately enable researchers to provide new treatments more efficiently and quickly to patients. Learn more.

Back to top


Cancer Genome Atlas Project

Emory University researchers will participate in a National Institutes of Health (NIH)-sponsored project analyzing the molecular basis of cancer called the Cancer Genome Atlas. Erwin G. Van Meir, PhD, co-director of Emory Winship Cancer Institute's brain tumor program and director of the laboratory for molecular neuro-oncology, was recently chosen by the NIH to supply samples and associated clinical history to support an unprecedented effort at cataloguing genetic alterations in glioblastoma, the most aggressive form of brain cancer.
Full story.
 


Bio-Medical Engineering

This collaborative effort between the Georgia Tech and the Emory University School of Medicine has launched Georgia into the forefront of biomedical research. A unique partnership between a public and private institution created the Department of Biomedical Engineering.  Learn more.


Georgia CORE State-wide Breast Cancer Trial Collaborative


Ruth O'Regan, MD, Emory associate professor and Georgia Cancer Coalition Distinguished Scholar, is the principal investigator for the first statewide cancer clinical trial in Georgia in which an investigator from an academic facility will collaborate with community-based oncology practices.  Learn more.

Back to top


Georgia Tech & Emory Center for Regenerative Medicine (GTEC)

Internationally recognized for its strengths and Novel applications of Regenerative Medicine, GTEC's success is built on the long-standing partnership between Georgia Tech, a top-rended engineering school and Emory University, one of the nation's finest medical schools.  Learn more.

Back to top


Emory University and the Georgia Institute of Technology Research Partnership

Initiated over 20 years ago, this partnership has developed into  one of the leading bioengineering and biomedical research and educational programs in the United States. It has grown to include a regenerative medicine center, a biotechnology incubator, and research collaborations in nanotechnology, bioinformatics, predictive health, and more.

Back to top